Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 4/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31548009 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL29121124 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL27945819 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL8086653 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL9684327 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL23857754 | 0.98 | CSNK1E (0.53) | CSNK1ECETPCNR2ALDH1A1CTRC | |
| SCHEMBL3338742 | 0.95 | CETP (0.44) | CSNK1ECETPCNR2ALDH1A1CYP3A4 | |
| SCHEMBL2076706 | 0.87 | CA1 (0.43) | CETPALDH1A1TSHRMAPK1 | |
| SCHEMBL22455862 | 0.84 | LTA4H (0.44) | ALDH1A1TSHRTDP1 | |
| SCHEMBL29172647 | 0.83 | CA1 (0.48) | ALDH1A1TSHRMAPK1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218231-A | Cyclobutane dicarboxylic acid platinum complex, wherein mesosome, preparation method, pharmaceutical composition and purposes | 天津谷堆生物医药科技有限公司 | 2019-09-10 | — | — | CN | disclosed |
| US-9321934-B2 | Method and material system for building models in layers | VOXELJET AG (DE) | 2016-04-26 | — | — | US | disclosed |
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20130302575-A1 | METHOD AND MATERIAL SYSTEM FOR BUILDING MODELS IN LAYERS | VOXELJET TECHNOLOGY GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| EP-1565507-A1 | NON-SETTING PROTECTED POLYISOCYANATES | Bayer MaterialScience AG (DE) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004046219-A1 | NON-SETTING PROTECTED POLYISOCYANATES | BAYER MATERIALSCIENCE AG (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102100-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, CYP4B1, NR1H4 | CSNK1E 3620/4885CETP 3175/4885CNR2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.